GenTech(SH:688596)2022-04-27 16:00Dividend and Profit Distribution - The company plans to distribute a cash dividend of 1.32 CNY per 10 shares, totaling 33,858,000 CNY (including tax) based on a total share capital of 256,500,000 shares as of December 31, 2021, resulting in a cash dividend payout ratio of 20.11%[5] - The board of directors has approved the profit distribution plan, which is subject to shareholder approval at the annual general meeting[5] Financial Performance - The company's operating revenue for 2021 was ¥1,836,764,431.27, representing a 65.63% increase compared to ¥1,108,985,484.16 in 2020[25] - The net profit attributable to shareholders for 2021 was ¥168,402,808.59, a 35.53% increase from ¥124,258,067.95 in 2020[25] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥137,449,567.90, showing an 84.61% increase from ¥74,455,483.92 in 2020[25] - The company's net cash flow from operating activities improved by ¥36,327,800, reaching -¥19,636,751.32 in 2021, compared to -¥55,964,976.84 in 2020[25] - The total assets at the end of 2021 were ¥3,507,658,393.50, a 24.12% increase from ¥2,826,014,927.27 at the end of 2020[25] - The net assets attributable to shareholders at the end of 2021 were ¥1,864,400,246.86, reflecting a 9.36% increase from ¥1,704,790,258.84 at the end of 2020[25] - The basic earnings per share for 2021 was ¥0.66, up 13.79% from ¥0.58 in 2020[27] Research and Development - The R&D expenditure as a percentage of operating revenue was 4.26% in 2021, a decrease of 0.47 percentage points from 4.73% in 2020[27] - Research and development investment reached CNY 78.22 million, a year-on-year increase of 49.02%, accounting for 4.26% of operating revenue[38] - The company has obtained a total of 135 intellectual property rights, including 25 invention patents, 103 utility model patents, 5 design patents, and 2 software copyrights[38] - The company has developed six core technologies in electronic specialty gases and chemical products, enhancing its production and sales capabilities[119] - The company has filed 24 new patent applications this year, with 22 patents granted, bringing the cumulative total to 166 applications and 135 granted[123] Market and Industry Position - The company actively expanded its market presence in emerging industries such as new energy and new materials, in addition to its existing focus on high-end manufacturing sectors[38] - The company has established itself as a leading domestic player in electronic process equipment, participating in the development of 7 national standards and serving major clients like SMIC and Samsung[84] - The company is focused on enhancing its core competitiveness through continuous innovation and improvement of product quality[38] - The company is committed to autonomous research and development, continuously optimizing its core technologies to enhance product purity and production efficiency[119] Operational Risks and Governance - The company has detailed various operational risks and corresponding mitigation measures in the report, emphasizing the importance of investor awareness regarding investment risks[4] - The company has confirmed that all board members were present at the board meeting, ensuring governance transparency[4] - There are no non-operational fund occupations by controlling shareholders or related parties reported[4] - The company does not have any special arrangements for corporate governance that would affect its operations[5] - The company has not violated any regulatory decision-making procedures regarding external guarantees[4] Future Outlook and Strategic Developments - The company expects continued growth driven by the expansion of downstream industries and effective cost control measures[27] - The company has stated that future plans and strategic developments are forward-looking statements and do not constitute substantive commitments to investors[5] - The company aims to achieve a 90% application rate of cloud technology and artificial intelligence by 2025, which will drive high-quality and intelligent development in the pharmaceutical equipment sector[109] Challenges and Risks - The company faces risks related to technology upgrades and potential loss of core technical personnel, which could impact its competitive edge[149][150] - The ongoing COVID-19 pandemic poses uncertainties that could impact the company's operations and supply chain efficiency[158] - The company faces risks related to market competition as the semiconductor industry heats up, potentially affecting product scarcity and customer retention[154] Subsidiaries and Investments - The company established several new subsidiaries in 2021, including Tongling Zhengfan Electronic Materials Co., Ltd. and Hongge Semiconductor Equipment (Shanghai) Co., Ltd.[172] - The company established two new subsidiaries: Zhengfan Baotai (Suzhou) Technology Co., Ltd. in November 2021 and Zhengfan Technology (Lishui) Co., Ltd. in December 2021[175] - The company made six new equity investments totaling ¥89,490,000, indicating a strategic expansion in its investment portfolio[188]